Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAA868 (Abelacimab) vs Apixaban in Atrial Fibrillation
NCT03398434Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2018
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of abelacimab in Atrial fibrillation (AFib), sponsored by Novartis. Planned start Oct 2018; status: withdrawn.
02
Drugs
abelacimab
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03398434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398434.